About Probable fibrosin-1
Probable fibrosin-1 (FBRS) is a protein
from Homo sapiens identified by UniProt accession
Q9HAH7, 460 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Probable fibrosin-1 |
| UniProt accession | Q9HAH7 |
| Gene | FBRS |
| Organism | Homo sapiens |
| Length | 460 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (34)
Diseases linked to this target (Open Targets).
- Short stature · score 0.34
- neurodegenerative disease · score 0.32
- mean platelet volume · score 0.07
- HbA1c measurement · score 0.06
- pulse pressure measurement · score 0.05
- platelet count · score 0.05
- C-reactive protein measurement · score 0.05
- Crigler-Najjar syndrome type 2 · score 0.04
- hemolytic anemia due to glutathione reductase deficiency · score 0.04
- Rotor syndrome · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9HAH7-F1 | alphafold | PREDICTED | 52.27 | — |
Amino-acid sequence (460 residues)
MFEKYPGKME GLFRHNPYTA FPPAVPGLPP GLPPAVSFGS LQGAFQPKST NPELPPRLGP VPSGLSQKGT QIPDHFRPPL RKPGKWCAMH VRVAYMILRH QEKMKGDSHK LDFRNDLLPC LPGPYGALPP GQELSHPASL FTATGAVHAA ANPFTAAPGA HGPFLSPSTH IDPFGRPTSF ASLAALSNGA FGGLGSPTFN SGAVFAQKES PGAPPAFASP PDPWGRLHRS PLTFPAWVRP PEAARTPGSD KERPVERREP SITKEEKDRD LPFSRPQLRV SPATPKARAG EEGPRPTKES VRVKEERKEE AAAAAAAAAA AAAAAAAAAT GPQGLHLLFE RPRPPPFLGP SPPDRCAGFL EPTWLAAPPR LARPPRFYEA GEELTGPGAV AAARLYGLEP AHPLLYSRLA PPPPPAAAPG TPHLLSKTPP GALLGAPPPL VPAPRPSSPP RGPGPARADR
Explore Probable fibrosin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets